ABSTRACT: GABA A receptors are ligand-gated ion channels that mediate inhibitory synaptic signaling in the CNS. Fluorescent probes with the ability to target these receptors can provide insights into receptor location, distribution and dynamics in live cells, while revealing abnormalities in their distribution and dynamics that could occur in a variety of diseases. We have developed fluorescent probes of GABA A receptors that are composed of a CdSe/ZnS core−shell nanocrystal (quantum dot; qdot) conjugated to pegylated derivatives of the GABA receptor agonists GABA and muscimol (GABA-qdots and muscimol-qdots, respectively). Quantitative fluorescence imaging was used to analyze the binding activity of these conjugates to α1β2γ2 GABA A and ρ1 GABA A receptors expressed in Xenopus oocytes. The selectivity of these conjugates for α1β2γ2 GABA A and ρ1 GABA A receptors was determined by their ability to compete with the antagonists bicuculline and methyl-(1,2,3,6-tetrahydropyridin-4-yl)phosphinic acid (TPMPA). Both GABA-and muscimol-qdots exhibited robust binding to both α1β2γ2 and ρ1 GABA A receptors. At α1β2γ2 receptors, pretreatment with bicuculline reduced conjugate binding by ≥8-fold on average, an extent far exceeding the reduction produced by TPMPA (∼30%). Conversely, at ρ1 receptors, pretreatment with TPMPA inhibited binding by ∼10-fold, an extent greatly exceeding the change produced by bicuculline (∼50% or less). These results indicate specific binding of muscimol-qdots and GABA-qdots to α1β2γ2 GABA A and ρ1 GABA A receptors in a manner that preserves the respective pharmacological sensitivities of these receptors to TPMPA and bicuculline, and encourage the use of qdot-conjugated neurotransmitter analogs as labeling agents at GABA A receptors.
γ-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter of the central nervous system. GABA A receptors, a class of ligand-gated ion channels, represent a major subtype of GABA receptors, and are important pharmacological targets for benzodiazepines, barbiturates, and anesthetics. Their structure is a pentameric arrangement of α, β, γ, δ, ε, π, and/or θ subunits.
1−4 GABA A -ρ (also known as GABA C ) receptors are a subfamily of GABA A receptors that consist of ρ subunits. 3,5−12 GABA A -non-ρ and GABA A -ρ receptors exhibit distinct pharmacological properties. For example, while GABA and muscimol (5-aminomethyl-3-hydroxyisoxazole) are agonists of both GABA A -non-ρ and GABA A -ρ receptors, bicuculline is an antagonist of GABA A -non-ρ receptors only, and (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) and 2-aminoethyl methylphosphonate are antagonists of GABA A -ρ receptors. 13−17 Quantum-dot-conjugated, chain-derivatized analogues of GABA receptor agonists 18 are potentially useful for fluorescence labeling of GABA receptors, allowing, for example, the study of location, distribution, and membrane dynamics of GABA receptors in live cell cultures. Cadmium selenide−zinc sulfide (CdSe/ZnS) core−shell nanocrystals, or quantum dots (qdots), are highly fluorescent semiconductor crystals with quantum yields approaching unity. 19 Their photostability allows continuous excitation for periods of hours, rather than minutes or seconds as currently achievable with organic fluorescent dyes. The emission spectra of core−shell nanocrystals are narrow and size-tunable, enabling their application in multiplex imaging studies. 20−23 Thus, qdot conjugates of biomolecules are an emerging alternative to dye conjugates in applications that require long acquisition times or high detection sensitivity.
To date, qdots have been conjugated to a variety of biomolecules, through acid−base interactions between the ligand and the surface of the qdot, 24 covalent attachment of the ligand to a polymer coating on the qdot, 25 or interactions between a biotinylated ligand and a streptavidin coat on the qdot. 26−39 Among the previously described types of qdot-based constructs that have been used to study membrane bound receptors are those consisting of small-molecule ligands conjugated to the qdot via a linear linker. For example, Gussin et al. 40 and Tomlinson et al. 41 have shown, by quantitative image analysis, that muscimol linked to highly fluorescent, AMP-coated CdSe/ZnS quantum dots via an aminohexanoyl spacer and a poly(ethylene glycol) chain (muscimol-qdot; ∼150−200 copies of muscimol/qdot; Figure 1A ) exhibits specific binding to Xenopus oocytes expressing ρ1 GABA A receptors, a homopentameric model of GABA A -ρ receptors. 5,11,42−45 Furthermore, the binding intensity is correlated with the number of muscimol-terminated chains joined to the qdot. 46 The high multivalency (e.g., number of muscimols bound to a given qdot; Figure 1A ) and other features of the previously described muscimol-qdot raise interesting questions about the nature of the binding interaction of this type of molecule with GABA receptors. In the present study, we have further investigated this interaction by determining whether muscimol-qdots ( Figure 1A ) and a closely related conjugate that incorporates GABA as the terminating ligand ( Figure 1B ) exhibit binding to α1β2γ2 GABA A receptors, a widely distributed GABA A receptor subtype. Specifically, we have asked whether interactions of the qdot-based conjugates with α1β2γ2 GABA A and ρ1 GABA A receptors preserve the selective sensitivity of these receptor subtypes to bicuculline and TPMPA antagonists. The results provide evidence for robust binding of muscimol-and GABA-qdots to α1β2γ2 GABA A as well as ρ1 GABA A receptors, and indicate marked subtypedependent inhibition of the conjugate/receptor interaction. Preliminary findings were reported at the 2009 meeting of the Society for Neuroscience. 47 ■ RESULTS AND DISCUSSION Synthesis of Ligand-Conjugated Quantum Dots. We synthesized a GABA-derivatized ligand, which was conjugated to the AMP-qdot polymer surface. Briefly, this ligand was composed of GABA derivatized with an aminohexanoyl linker that was subsequently attached to an amino-terminated polydisperse poly(ethylene glycol) (PEG) chain with an average mass of 3400 Da. This ligand was conjugated to the AMP surface of the qdot using EDC coupling as previously described. 40 This yielded GABA-conjugated qdots that contained ∼150−200 GABA ligands attached to the qdot ( Figure 1B) . Preparation of the muscimol-qdot conjugate followed previously described procedures. 40 Binding of Conjugates to GABA Receptor-Expressing Oocytes. To test for specific binding of the GABA-conjugated qdots (GABA-qdots) and muscimol-conjugated qdots (muscimol-qdots) to GABA A receptors, we incubated the conjugates, at approximately 30 nM (qdot concentration), with oocytes expressing either α1β2γ2 or homopentameric ρ1 GABA A receptors, or with nonexpressing (NE) oocytes. Incubation of α1β2γ2-expressing and ρ1-expressing oocytes with either muscimol-qdots or GABA-qdots yielded a fluorescent halo at the oocyte surface membrane, indicating binding of the qdotconjugate to the oocyte surface. This halo was absent following similar treatment of NE oocytes (Figure 2 ). Net halo fluorescence intensity (FI), that is, halo intensity minus surround background intensity, 40, 46 was significantly higher in α1β2γ2-or ρ1-expressing oocytes than in NE oocytes, with either muscimol-qdots [FI(α1β2γ2) vs FI(NE): 51.53 (mean) ± 21.66 (SD) (n = 9) vs 10.74 ± 9.62 (n = 10), p < 0.0001; FI(ρ1) vs FI(NE): 65.81 ± 14.43 (n = 8) vs 10.74 ± 9.62 (n = Figure 3 illustrates the development of fluorescence intensity over time. At all time points the net fluorescence obtained with nonexpressing oocytes was relatively low, whereas the fluorescence obtained with both qdot conjugates on GABA receptor-expressing oocytes was significantly higher than background. Average FI values obtained with a given GABA receptor subtype were slightly higher for muscimol-qdots than for GABA-qdots. As the potencies of free muscimol and GABA at the two receptor types are comparable, 48−50 this modest difference may have reflected differing orientations of the two terminating ligands in the receptor's GABA-binding pocket due to chain-derivatization. The relative plateaus evident in the graphs are consistent with previous reports, which showed that ∼80% of the maximal fluorescence intensity was reached after a 5 min incubation. 40, 46 Competition, by Free Muscimol or Free GABA, of Conjugate Binding to GABA Receptor-Expressing Oocytes. In competition experiments, we asked whether preincubation of oocytes with free muscimol or GABA decreases binding of the qdot conjugate. To assess competition by free ligand, we first incubated the oocytes for 15 min with free GABA or free muscimol at a fixed concentration (500 μM), and then with a solution containing both the same free ligand (500 μM) and a given qdot conjugate (30 nM). We first consider the results obtained with the use of GABA-qdots and free GABA as competitor. The two panels at the upper left of Figure 4 show representative images obtained with α1β2γ2- . These results, which are consistent with those previously reported, 40 indicated that under all of the investigated conditions, competition with free ligand markedly decreased the fluorescence halo. Figure 5 shows mean net fluorescence intensities of the halo when GABA-qdot and muscimol-qdot conjugates were competed with free GABA or free muscimol for binding to oocytes expressing α1β2γ2 (left) or ρ1 receptors (right). The values obtained when the oocytes were incubated with GABA and the qdot conjugate (open blue and red symbols) are relatively low (i.e., mean FI not different from background), by contrast with the values obtained in the absence of competitor (filled blue and red symbols). The effect of added competitor on mean net fluorescence intensity after a fixed period of treatment can be represented as the FI value determined under a given condition (i.e., given qdot conjugate and receptor type) with added competitor normalized to that determined under the same condition in the absence of competitor. Table 1 reports the normalized results obtained when the period of incubation with coapplied qdots and competitor was 15 min. For example, for both GABA-qdots and muscimol-qdots, when FI values obtained at t =15 min for α1β2γ2-and ρ1-expressing oocytes in the presence of free GABA were normalized to FI values obtained under similar conditions but in the absence of GABA, the average ratio was 0.01−0.14 ( Table 1, lines 3 and  8) . That is, the presence of GABA greatly reduced the FI. When the oocytes were incubated with GABA-qdot and muscimolqdot conjugates with competition with free muscimol (yellow and green symbols), FI values obtained at t = 15 min were also close to zero. Specifically, with GABA-qdots, FI values obtained with muscimol competition were 0.00 ± 0.00 (n = 2) and 12.23 ± 14.15 (n = 4) for oocytes expressing α1β2γ2 and ρ1 receptors, respectively. With muscimol-qdots, muscimol competition yielded FI values of 3.70 ± 5.23 (n = 6) and 0.78 ± 1.11 (n = 2) for oocytes expressing α1β2γ2 and ρ1 receptors, respectively. Normalization of the data obtained at t = 15 min with muscimol competition showed that fluorescence in the presence of muscimol was, on average, 0−0.25 of the FI value obtained in the absence of competitor (Table 1, lines 2  and 7) . From these results, we conclude that free GABA and free muscimol inhibit the binding of GABA-qdots and muscimol-qdots to α1β2γ2-and ρ1-expressing oocytes.
Competition of Muscimol-qdot or GABA-qdot Binding with Bicuculline or TPMPA. In experiments similar in design to that used for the tests of GABA and muscimol as competitors, oocytes expressing α1β2γ2 or ρ1 GABA A receptors were incubated with GABA-qdots or muscimolqdots, together with methyl-(1,2,3,6-tetrahydropyridin-4-yl)-phosphinic acid (TPMPA), a GABA A ρ-subtype receptor antagonist, or with bicuculline (GABA A non-ρ receptor antagonist). 7,13−17 Fluorescence images presented in panels A−D of Figure 6 show results obtained with TPMPA competition. As illustrated in Figure 6 , A and C, TPMPA coapplied with GABA-qdots (A) and muscimol-qdots (C) to oocytes expressing α1β2γ2 GABA A receptors preserved a visually substantial fluorescence halo, but markedly reduced the fluorescence halo at oocytes expressing ρ1 GABA A receptors (B and D). Conversely, for both qdot preparations, bicuculline (Figure 6E−H) essentially eliminated the fluorescence halo at α1β2γ2-expressing oocytes (E and G), but had relatively little effect at ρ1-expressing oocytes (F and H). These visual observations were confirmed when fluorescence intensity of the halos was quantified. As shown in the left panel of Figure 7 , the binding of GABA-qdots and muscimol-qdots to α1β2γ2 receptors was inhibited by bicuculline (yellow and green symbols). Analysis of fluorescence intensities at α1β2γ2 oocytes, determined in the presence of bicuculline, at t = 15 min yielded 4.35 ± 8.70 (n = 4) and 1.73 ± 2.33 (n = 4) for GABA-qdots and muscimol-qdots, respectively; these were significantly lower than FIs obtained in the absence of competitor (p = 0.0095 for GABA qdots; and p = 0.0005 for muscimol qdots). Furthermore, the effects of TPMPA (open blue and red symbols) on the binding of GABA qdots and muscimol qdots at α1β2γ2 were modest, with FI = 27.55 ± 1.39 (n = 2) and 35.65 ± 15.39 (n = 3), respectively, at t = 15 min; these values did not differ significantly from values at t = 15 min obtained in the absence of competitor (p = 0.2775 for GABA-qdots and p = 0.1318 for muscimol-qdots) (filled blue and red symbols). By contrast, as shown in the right panel of Figure 7 , the binding of GABA-qdots and muscimol-qdots to 40, 41, 46 by examining binding of the muscimolqdot preparation at non-ρ GABA A receptors, and investigating the pharmacological specificity of receptor binding by both qdot conjugates. The results demonstrate the binding of both muscimol-qdots and GABA-qdots to both α1β2γ2 GABA A and ρ1 GABA A receptors expressed in Xenopus oocytes. This binding is specific, that is, receptor-dependent, since no binding by either conjugate to nonexpressing oocytes was observed. Furthermore, the specificity of the investigated conjugates for GABA A non-ρ and GABA A ρ-subtype receptors is pharmacologically significant. That is, in both receptor types, free GABA and free muscimol compete with binding of both conjugates. In addition, the binding of both conjugates to α1β2γ2 GABA A receptors is inhibited by bicuculline, an antagonist of GABA A non-ρ receptors, and binding of both to ρ1 GABA A receptors is inhibited by TPMPA, a GABA A ρ-subtype receptor antagonist.
The robust and selective binding activity of the qdot conjugates investigated here suggests a number of future applications for these structures. One such application is their use in tracking the movement of single GABA A receptors on cell surfaces. 51 As emphasized in previous studies, the high fluorescence and nonbleaching nature of these structures offer distinct advantages by comparison with organic fluorophores. 19−23 Furthermore, these conjugates may prove valuable as an alternative to immunolabeling for identifying the locations of GABA A receptors in neural tissue. A further potential application is one in which qdot-attached linear chains terminated with a reagent other than GABA or muscimol are substituted for some of the GABA-or muscimol-terminated chains, to yield a qdot-based scaffold that can be customized for specific applications. For example, a qdot conjugate possessing biotin-terminated as well as GABA-or muscimol-terminated chains could perhaps function as a scaffold that enables the trapping of single, isolated GABA A -expressing cells on a streptavidin-coated surface for cell biological or physiological study.
A broad question of interest raised by the present findings is the dependence of GABA A receptor binding affinity and on/off kinetics of the investigated qdot conjugates on structural features such as ligand valency and the length/composition of the linker that joins these ligands to the qdot. The present procedures for obtaining quantitative FI data can be applied generally to determining binding parameters, including the effects of competitors and other pharmacological agents. However, the precise determination and mechanistic interpretation of binding parameters will likely require improvement in the precision with which the absolute number of ligands bound to the qdot (i.e., qdot valency) can be controlled. That is, at present, the maximal number of ligand-terminated chains bound to a given qdot appears to vary from ∼150 to ∼200. 40, 46 In addition, because GABA A receptors possess multiple GABAbinding sites (two on α1β2γ2; five on ρ1), kinetic models derived in such studies will need to consider the contributions of multiple binding modes to the interaction of the multivalent conjugate with a given receptor. Also important will be testing of the possibility that a given copy of the conjugate "bridges" neighboring receptors on the cell surface. 46 The addressing of these issues will likely prove valuable for widening the application of qdot-based multivalent conjugates to the targeting of cell surface receptor proteins. carbodiimide hydrochloride (EDC), Dowex 50WX4-50 exchange resin, and pyridine were obtained from Aldrich Chemical Corporation (Milwaukee, WI). Methylene chloride was obtained from Fisher BioReagents Scientific (Fair Lawn, NJ) and used without purification. Magnesium sulfate was obtained from VWR International (West Chester, PA). All NMR measurements were performed using a Bruker 300 MHz machine. Chemical shifts were measured relative to TMS.
Synthesis of Conjugates. Muscimol-conjugated quantum dots were synthesized using previously described protocols. 40, 46 The GABA ligand used in these studies was composed of GABA attached to polydisperse PEG 3400 via a short (6-aminohexanoyl; AH) spacer. The other end of the PEG was terminated with an amino functionality, and this formed the point of attachment to the AMP coating on the qdot surface. The GABA ligand (IV) was synthesized as outlined in Figure 8 . N-Hydroxysuccinimide ester (BOC-AH-NHS), synthesized as described by Doughty et al., 52 was reacted with γ-aminobutyric acid (GABA) to yield (I) in a 44% yield. The BOC protecting group was subsequently removed with trifluoroacetic acid to give AH-GABA (II) in a 68% yield. This was coupled to BOC-NH-PEG-CONHS to give the BOC protected intermediate (BOC-NH-PEG-AH-GABA) (III), which was converted to the GABA ligand (NH 2 -PEG-AH-GABA) (IV) by treatment with trifluoroacetic acid. MALDI-MS of the NH 2 -PEG-AH-GABA was consistent with compound (IV).
4-(6-(tert-Butoxycarbonylamino)hexanamido)butanoic Acid (I). 6-tert-Butoxycarbonylaminohexanoic acid 2,5-dioxopyrrolidin-1-yl ester (4 g, 12.2 mmol) and γ-aminobutanoic acid (1.25 g, 12.2 mmol) were dissolved in dry pyridine (50 mL). The solution was stirred at ambient temperature for 18 h and then evaporated under reduced pressure. The resulting residue was washed with diethyl ether (1 × 100 mL) and then was dissolved in methylene chloride (100 mL). This was washed with hydrochloric acid (2M, 2 × 50 mL) and dried over anhydrous magnesium sulfate. The solution was filtered and evaporated to give 1.7 g (44%) of 4-(6-(tert-butoxycarbonylamino)-hexanamido)butanoic acid as a yellow oil. 4-(6-Aminohexanamido)butanoic Acid Ammonium Salt (II). 4-(6-(tert-Butoxycarbonylamino)hexanamido)butanoic acid (1.6 g, 5 mmol) was dissolved in methylene chloride (2 mL), and trifluoroacetic acid (2 mL) was added. The solution was stirred at ambient temperature for 1 h and then evaporated under reduced pressure. The resulting residue was dissolved in deionized water (2 mL); the product was purified on Dowex 50WX4-50 exchange resin that was initially eluted with deionized water and then eluted with amonium hydroxide solution. The fractions containing the 4-(6-aminohexanamido)-butanoic acid were visualized on silica TLC plates by staining with ninhydrin, and these were evaporated under reduced pressure to give 0.79 g (68%) of 4-(6-aminohexanamido)butanoic acid ammonium salt (II) as a white solid. 1 BOC-Protected GABA Derivative (III). An amount of 0.2 g of tertbutyloxycarbonyl (BOC) amine-PEG-activated acid (BOC-NH-PEGNHS) was weighed out in a round-bottomed flask, and methylene chloride (100 mL) was added. Then 0.016 g of 4-(6-aminohexanamido)butanoic acid ammonium salt (II) was dissolved in dry pyridine (2 mL), and this solution was added to the methylene chloride solution. The resulting mixture was stirred at ambient temperature for 48 h and then evaporated under reduced pressure. The crude product was washed with diethyl ether (6 × 100 mL) and dried under reduced pressure to yield 0.2 g of the BOC protected GABA derivative (III) as a white solid.
Deprotected GABA Derivative (IV). An amount of 0.16 g of the BOC protected GABA derivative (III) was dissolved in methanol (5 mL), and trifluoroacetic acid (3 mL) was added. This solution was stirred at ambient temperature for 2 h; the solution was then evaporated under reduced pressure. The final product was washed with diethyl ether (10 × 100 mL) and dried under reduced pressure to give 0.12 g of the GABA derivative (IV) as a white solid.
Ligand Coupling. NH 2 -PEG-AH-GABA was conjugated to terminating carboxyl groups on the AMP coated qdots using 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC). A volume of 0.1 mL of an 8 μM solution of qdots was placed in a vial equipped with a stir bar. To this was added 0.3 mL of borate buffer (pH 8.5) that contained 3 mg (1000 equiv) of the GABA ligand (NH 2 -PEG-AH-GABA) (IV). Then N-hydroxysuccinimide (72 μg, 0.63 μmol) dissolved in borate buffer (0.1 mL) was added. This was followed by the addition of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) (0.12 mg, 0.63 μmol) dissolved in borate buffer (0.1 mL). The mixture was stirred at room temperature for 2 h, then purified by passage through a Sephadex G-50 column, and eluted with borate buffer (pH 8.5). The fluorescent fractions were combined to yield the purified GABA-functionalized qdots (GABA-PEG-qdots). The concentration of the resulting GABA-conjugated qdots was determined to be 580 nM using UV−visible spectroscopy, based on measurement of the absorption feature at 600 nm and use of 6.5 × 10 5 M −1 cm −1 as extinction coefficient. The GABA-conjugated qdots were characterized using agarose gel electrophoresis.
Ligand loading of the qdot was governed by the number of molar equivalents (relative to that of the qdot) of added ligand and EDC 31, 46 as well as by steric constraints and the availability of free carboxylic groups on the AMP-coated qdot surface. With muscimol-terminated ligand, use of a large excess of ligand (2000 equivalents) led to precipitation of the conjugate, 40 perhaps due to ligand cross-linking through electrostatic or hydrogen bonding interactions or to general insolubility. Quantum dots with an excessively high loading of ligand might be deleterious for studies aimed at the tracking of single GABA receptors, particularly if the receptors were expressed at high density on the cell surface.
Oocyte Preparation. All animal procedures adhered to institutional policies and to the Statement for the Use of Animals in Ophthalmic and Vision Research adopted by the Association for Research in Vision and Ophthalmology (ARVO). Oocytes were obtained from Xenopus laevis toads (Xenopus One, Ann Arbor, MI), and α1β2γ2 GABA A (rat α1, rat β2, human γ2 subunits) or homopentameric human ρ1 GABA A receptors were expressed in the oocytes through injection of RNA synthesized in vitro (mMessage mMachine, Ambion/Applied Biosystems by Life Technologies, Austin, TX) as previously described. 9, 18 Oocytes that were not injected with RNA, that is, did not express the GABA A receptors, were used as controls.
Quantitative Fluorescence Microscopy. Visualization and quantification procedures relevant to the fluorescence analysis of oocytes expressing α1β2γ2 GABA A receptors or ρ1 GABA A receptors, and (control) nonexpressing (NE) oocytes followed methods similar to those previously described. 40, 46 Specifically, fluorescence and brightfield images were obtained from oocytes positioned in glass-bottom dishes (MatTek Corp., Ashland, MA) and incubated for defined periods in physiological solution supplemented with the test components. Fluorescence was measured using a confocal microscope (Leica model DM-IRE2 with 20× objective; λ excitation = 476 nm; λ emission = 580−620 nm; peak emission λ = 600−605 nm). Microscope settings relevant to excitation illumination and detection of fluorescence emission were established at the beginning of each series of experiments and remained unchanged for the entire group of measurements. Experiments on a given day were performed on a single batch of oocytes and employed a single preparation of test solutions. Each fluorescence image was quantified (0−255 scale) using MetaMorph version 7.0r4 software (Universal Imaging Corp., Downingtown, PA), as previously described. 40, 46 Briefly, the arclike border of the oocyte was traced and it included 500−725 pixels (i.e., data points). For determination of background fluorescence (fluorescence of the medium bathing the oocyte), the line used to determine the border fluorescence was replicated to cover a representative region in the medium. For each image, the fluorescence intensities in the pixels along the two segmented lines (at the oocyte border and background) were then obtained. Net fluorescence intensity (FI) in each image was defined as the difference in the mean fluorescence intensity in the two lines, each consisting of a total of I pixels: 
where BDFI i and BGFI i are fluorescence intensities of the ith pixel in the oocyte border and background, respectively. Statistical Methods. The segmented lines representing the oocyte border and background within each image consisted of ∼500−725 data points, or equivalently, each image corresponded with 1000− 1450 data points. Because of the large number of data points representing each image, we determined the net fluorescence intensity FI for each image and then used a t test to compare the FI obtained for a given pair of experimental conditions. Because this approach (i.e., single data point per image) is highly conservative in terms of statistical power, compared with an alternative approach that compares conditions using a hierarchical method for all of the pixel values in each image (1000−1450 data points per image), we further decided not to correct the determined p-values for multiple comparisons. Any p-value < 0.05 resulting from a one-sided t test was considered to be statistically significant. 
